DDInter1377 DDInter1763
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Paclitaxel {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Paclitaxel {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Paclitaxel {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Paclitaxel {u} (Compound) upregulates {v} (Gene) PRKCQ
PRKCQ {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Paclitaxel {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Paclitaxel {u} (Compound) upregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Paclitaxel {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Febrile neutropenia {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Paclitaxel {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Paclitaxel (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound)
Paclitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Paclitaxel (Compound) downregulates MYC (Gene) and MYC (Gene) is upregulated by Temsirolimus (Compound)
Paclitaxel (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is upregulated by Temsirolimus (Compound)
Paclitaxel (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Temsirolimus (Compound)
Paclitaxel (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is downregulated by Temsirolimus (Compound)
Paclitaxel (Compound) causes Febrile neutropenia (Side Effect) and Febrile neutropenia (Side Effect) is caused by Temsirolimus (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Paclitaxel (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)